KNSA · Kiniksa Pharmaceuticals, Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M | - |
| Cost of Revenue | $77.67M | $60.91M | - | - | $9.10M | - |
| Gross Profit | $599.89M | $362.33M | - | - | $29.44M | - |
| R&D | $96.85M | $111.62M | $76.10M | $65.49M | $99.30M | $112.04M |
| SG&A | $196.27M | $168.01M | $129.43M | $97.95M | $45.32M | $45.32M |
| Total Operating Expenses | - | - | - | - | - | $157.36M |
| D&A | $1.55M | $1.70M | $2.34M | $2.40M | $2.40M | $2.40M |
| Operating Income | $77.22M | ($45.62M) | ($25.20M) | $9.77M | ($156.64M) | ($157.36M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $29.86M | $7.04M | ($30.74M) | ($172.34M) | $1.39M | $5.15M |
| Net Income | $59.01M | ($43.19M) | $14.08M | $183.36M | ($157.92M) | ($161.38M) |
| EPS - Basic | $0.80 | ($0.60) | $0.20 | $2.64 | ($2.61) | - |
| EPS - Diluted | $0.75 | ($0.60) | $0.20 | $2.60 | ($2.61) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $165.60M | $183.58M | $107.95M | $122.72M | $122.47M | $114.04M |
| Accounts Receivable | $15.59M | $41.72M | $21.27M | $12.66M | $3.98M | - |
| Inventory | $54.90M | $26.36M | $31.12M | $21.60M | $3.67M | - |
| Accounts Payable | $2.03M | $2.04M | $8.25M | $7.90M | $1.87M | $503.0K |
| Current Assets | $527.18M | $331.80M | $276.30M | $243.06M | $196.45M | $333.25M |
| Total Assets | $763.63M | $580.55M | $526.32M | $459.67M | $232.80M | $349.46M |
| Current Liabilities | $139.18M | $100.62M | $63.67M | $47.07M | $44.82M | $31.85M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $196.03M | $142.12M | $87.48M | $63.52M | $47.76M | $37.53M |
| Stockholders' Equity | $567.61M | $438.44M | $438.84M | $396.15M | $185.04M | $311.94M |
| Retained Earnings | ($462.14M) | ($521.14M) | ($477.95M) | ($492.03M) | ($675.40M) | ($517.47M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $137.99M | $25.69M | $13.30M | $5.81M | ($126.30M) | ($136.53M) |
| Investing Cash Flow | ($188.99M) | $37.67M | ($29.56M) | ($8.08M) | $128.63M | ($23.44M) |
| Financing Cash Flow | $33.02M | $12.27M | $1.50M | $2.52M | $5.88M | $227.09M |
| CapEx | $1.57M | $277.0K | $130.0K | $105.0K | $415.0K | $283.0K |
| Free Cash Flow | $136.42M | $25.41M | $13.17M | $5.70M | ($126.71M) | ($136.81M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 88.5% | 85.6% | - | - | 76.4% | - |
| Operating margin | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% | - |
| EBITDA margin | 11.6% | -10.4% | -8.5% | 5.5% | -400.1% | - |
| Net margin | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | - |
| Free cash flow margin | 20.1% | 6.0% | 4.9% | 2.6% | -328.7% | - |
| FCF / Net income | 2.31 | -0.59 | 0.94 | 0.03 | 0.80 | 0.85 |
| R&D / Revenue | 14.3% | 26.4% | 28.2% | 29.7% | 257.6% | - |
| SG&A / Revenue | 29.0% | 39.7% | 47.9% | 44.5% | 117.6% | - |
| Effective tax rate | 33.6% | - | - | -1563.0% | - | - |
| Return on assets | 7.7% | -7.4% | 2.7% | 39.9% | -67.8% | -46.2% |
| Return on equity | 10.4% | -9.9% | 3.2% | 46.3% | -85.3% | -51.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.79 | 3.30 | 4.34 | 5.16 | 4.38 | 10.46 |
| Quick ratio | 3.39 | 3.04 | 3.85 | 4.71 | 4.30 | 10.46 |
| Cash ratio | 1.19 | 1.82 | 1.70 | 2.61 | 2.73 | 3.58 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.35 | 1.32 | 1.20 | 1.16 | 1.26 | 1.12 |
| Liabilities / Assets | 0.26 | 0.24 | 0.17 | 0.14 | 0.21 | 0.11 |
| Efficiency | ||||||
| Asset turnover | 0.89 | 0.73 | 0.51 | 0.48 | 0.17 | - |
| Inventory turnover | 1.41 | 2.31 | - | - | 2.48 | - |
| Days sales outstanding | 8d | 36d | 29d | 21d | 38d | - |
| Days inventory outstanding | 258d | 158d | - | - | 147d | - |
| Days payable outstanding | 10d | 12d | - | - | 75d | - |
| Cash conversion cycle | 257d | 182d | - | - | 110d | - |
| Valuation | ||||||
| P / E | 55.0x | - | 87.7x | 5.8x | - | - |
| P / B | 5.7x | 3.2x | 2.9x | 2.7x | 3.9x | - |
| P / S | 4.8x | 3.3x | 4.7x | 4.8x | 18.9x | - |
| EV / EBITDA | 39.3x | - | - | 76.6x | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 60.1% | 56.6% | 22.7% | 471.2% | - | - |
| Revenue CAGR (3y) | 45.5% | 122.3% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | 65.6% | - | - | - | - | - |
| Operating income growth (YoY) | - | -81.0% | - | - | 0.5% | 7.4% |
| Net income growth (YoY) | - | - | -92.3% | - | 2.1% | 0.3% |
| EPS growth (YoY) | - | - | -92.3% | - | - | - |
| EPS CAGR (3y) | -33.9% | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 436.8% | 92.9% | 131.0% | - | 7.4% | 15.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 29.5% | -0.1% | 10.8% | 114.1% | -40.7% | 38.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$677.56M totalPharmaceutical Segment$677.56M · 100.0%
Product / service
$677.56M totalProduct$677.56M · 100.0%
Geographic
$677.56M totalUS$676.75M · 99.9%
GB$814.0K · 0.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.27
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Kiniksa Pharmaceuticals against the 5 most active filers in the same SIC group.